NMDA Receptor Modulation as a Bidirectional Axis: Reframing Ketamine's Antagonism Against Glycine-Site Enhancement, with a Proposed Extension to Sleep-Disrpted
Melissa Carter
Zenodo (CERN European Organization for Nuclear Research) July 14, 2026 preprint DOI: 10.5281/zenodo.21364655 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Interventions | ketamine sarcosine D-serine |
| Topics | Ketamine Esketamine |
| Keywords | Nmda receptor Schizophrenia object-oriented programming Memantine Sleep system call Inverse agonist |
| Key findings | Glycine-site enhancers represent an underexplored candidate for sleep restoration in NMDA-hypofunction states such as sleep-disrupted neurodegenerative disease. |
Abstract
This paper proposes treating N-methyl-D-aspartate (NMDA) receptor modulation as a single bidirectional pharmacological axis, with ketamine (an NMDA antagonist) and glycine-site enhancers such as sarcosine and D-serine (NMDA agonists/enhancers) sitting at opposite poles. Both directions have documented human trial evidence, but in separate literatures — ketamine in anesthesia and depression research, glycine-site enhancers in schizophrenia adjunct treatment. This paper reviews that established evidence, distinguishes anesthesia-induced unconsciousness from NMDA-mediated restorative sleep architecture, and proposes a falsifiable extension: that glycine-site enhancers, as the pharmacological inverse of ketamine, represent an underexplored candidate for sleep restoration in NMDA-hypofunction states such as sleep-disrupted neurodegenerative disease. Specific, testable predictions are outlined, along with clearly stated limitations distinguishing established findings from hypothesis-stage claims.
Comparable studies
Other narrative reviews on ketamine, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms | 2018 | Review | |
| Mechanisms of Ketamine Action as an Antidepressant | 2018 | Review | |
| Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation Adults with treatment-resistant depression | 2021 | Review | |
| Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings) | 2013 | Review | |
| A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders | 2017 | Review and consensus statement |